Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Related News Articles

Headline
The Centers for Medicare…
Headline
The AHA’s Institute for Diversity and Health Equity today named Duane Elliott Reynolds as its new president and CEO.
Blog
Axios' The poor state of U.S hospital quality (December 1, 2018) gives an incomplete view on the state of quality and safety in America’s hospitals and health…
Headline
The Food and Drug Administration yesterday released revised draft guidance for facilities that compound human drugs as outsourcing facilities.
Headline
Inpatient rehabilitation facilities and long-term care hospitals have until Jan. 2 to review confidential provider reports based on quality data from second-…
Headline
The Institute for Healthcare Improvement today released a white paper intended to help health system boards assess and improve their quality oversight…